The Molecular Imaging Laboratory, which is part of the Sloan Kettering Institute’s Molecular Pharmacology and Chemistry Program, is focused on both the development of new molecular probes for cross-sectional, multimodality imaging (MRI, PET and optical) and translational research in molecular imaging. This ranges from basic science to clinical translation, as well as clinical molecular imaging observations to basic science tumor analysis. The objective of the research is to further improve our understanding of in vivo tumor biology and interaction with its microenvironment, with the ultimate goal of early tumor detection and characterization and the development of imaging as a prognostic, predictive, and early-response biomarker.